New Drugs and Combinations in the Management of Hematological Malignancies and Rare Diseases

Topic Information

Dear Colleagues,

We are pleased to announce a Topic titled “New Drugs and Combinations in the Management of Hematological Malignancies and Rare Diseases”, in cooperation with the 1st International Online Conference on Hematology (IOCHE 2026). We warmly welcome full manuscript submissions from conference participants as well as researchers from the broader scientific community.

The IOCHE 2026 will be held virtually on 28–30 October 2026. This international scientific event aims to bring together researchers and scholars to discuss a wide range of topics in hematology. It will serve as a platform to cover a broad spectrum of subjects and to publish the latest advances in the field of hematology, which have far-reaching impacts on diseases such as anemia, leukemia, and rare blood diseases. Thematic sessions will cover topics including:

• Multiple Myeloma
• Acute Myeloid Leukemia
• Acute Lymphoblastic Leukemia
• Non-Hodgkin Lymphoma
• Hodgkin Lymphoma
• CML and Myeloproliferative Neoplasms
• Stem Cell Transplantation and New Cellular Therapies
• Rare Diseases

This Topic will focus on publishing various studies on new drugs and combinations in the management of hematological malignancies and rare diseases. Topics of interest include, but are not limited to, the following:

• Next-generation targeted inhibitors in hematological malignancies
• Novel bispecific and multi-specific antibodies for blood cancers
• Antibody-drug conjugates in hematological malignancies (lymphomas, myelomas, and leukemias)
• Advanced cell therapies and resistance mechanisms in hematology
• Innovative epigenetic agents for malignant hematological disorders
• Novel complement inhibitors for rare hematological diseases like PNH and aHUS
• Gene editing therapies for rare inherited hemoglobinopathies (e.g., sickle cell disease and thalassemia)
• RNA-targeted therapeutics in rare hematological disorders
• Small-molecule therapies for rare metabolic diseases affecting the hematopoietic system
• Chemo-free regimens combining targeted and immune therapies in hematological malignancies
• Synergistic drug combination mechanisms overcoming clonal evolution
• Combination strategies addressing primary and acquired drug resistance
• Preclinical models for screening novel therapeutic combinations
• Cumulative toxicity profiles and management strategies in multi-drug combination regimens
• Biomarkers and MRD monitoring for combination therapy responses
• Real-world evidence on new drugs for rare hematological diseases
• AI-driven drug repurposing and combination synergy prediction for hematological malignancies and rare hematological disorders

We encourage contributions from all researchers whose work aligns with the themes outlined above.

We look forward to your valuable submissions.

Prof. Dr. Claudio Cerchione
Prof. Dr. Aurelio Maggio
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Cancers cancers	4.8	9.0	2009	19.1 Days	CHF 2900	Submit
Hemato hemato	0.7	1.9	2020	21.8 Days	CHF 1200	Submit
Hematology Reports hematolrep	1.9	2.3	2009	29.4 Days	CHF 1600	Submit
Journal of Clinical Medicine jcm	3.3	5.2	2012	18.5 Days	CHF 2600	Submit
Thalassemia Reports thalassrep	2.4	-	2011	42.6 Days	CHF 1000	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers